Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and
either kill them or deliver tumor-killing substances to them without harming normal cells.
Beta-glucan, isotretinoin, and sargramostim may increase the effectiveness of monoclonal
antibody 3F8 by making tumor cells more sensitive to the monoclonal antibody. Combining
different types of biological therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving beta-glucan, isotretinoin, and
sargramostim together with monoclonal antibody 3F8 works in treating patients with
neuroblastoma that has not responded to previous treatment.